

Pharmaceutical Biotechnology • Volume 1

Protein Pharmacokinetics and Metabolism

**Edited by
Bobbe L. Ferraiolo,
Marjorie A. Mohler,
and
Carol A. Gloff**

0052273

Protein Pharmacokinetics and Metabolism

Edited by

Bobbe L. Ferraiolo

*R. W. Johnson Pharmaceutical Research Institute
Spring House, Pennsylvania*

Marjorie A. Mohler

*Genentech, Inc.
South San Francisco, California*

and

Carol A. Gloff

*Alkermes, Inc.
Cambridge, Massachusetts*

Plenum Press • New York and London

Library of Congress Cataloging-in-Publication Data

Protein pharmacokinetics and metabolism / edited by Bobbe L.

Ferraiolo, Marjorie A. Mohler, and Carol A. Gloff.

p. cm. -- (Pharmaceutical biotechnology ; v. 1)

Includes bibliographical references and index.

ISBN 0-306-44151-9

1. Proteins--Metabolism. 2. Protein drugs--Pharmacokinetics.

I. Ferraiolo, Bobbe L. II. Mohler, Marjorie A. III. Gloff, Carol

A. IV. Series.

[DNLM: 1. Proteins--metabolism. 2. Proteins--pharmacokinetics.

QU 55 P9674]

QP551.P69747 1992

615'.7--dc20

DNLM/DLC

for Library of Congress

92-49392

CIP

ISBN 0-306-44151-9

© 1992 Plenum Press, New York

A Division of Plenum Publishing Corporation

233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Protein Pharmacokinetics and Metabolism

Pharmaceutical Biotechnology

Series Editor: Ronald T. Borchardt

The University of Kansas

Lawrence, Kansas

Volume 1 PROTEIN PHARMACOKINETICS AND METABOLISM
Edited by Bobbe L. Ferraiolo, Marjorie A. Mohler,
and Carol A. Gloff

Volume 2 STABILITY OF PROTEIN PHARMACEUTICALS,
Part A: Chemical and Physical Pathways of Protein
Degradation
Edited by Tim J. Ahern and Mark C. Manning

Volume 3 STABILITY OF PROTEIN PHARMACEUTICALS,
Part B: *In Vivo* Pathways of Degradation and Strategies
for Protein Stabilization
Edited by Tim J. Ahern and Mark C. Manning

Volume 4 BIOLOGICAL BARRIERS TO PROTEIN DELIVERY
Edited by Kenneth L. Audus and Thomas J. Raub

Volume 5 STABILITY AND CHARACTERIZATION OF PROTEIN
AND PEPTIDE DRUGS: Case Histories
Edited by Y. John Wang and Rodney Pearlman

Contributors

- Robert A. Baughman, Jr.* • Research and Development, Emisphere Technologies, Hawthorne, New York 10532
- Gerhard Baumann* • Center for Endocrinology, Metabolism, and Nutrition, Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611
- Jennifer E. Cook* • Department of Safety Evaluation, Genentech, Inc., South San Francisco, California 94080
- Paul A. Cossum* • Department of Preclinical Development, Isis Pharmaceuticals, Carlsbad, California 92008
- Bobbe L. Ferraiolo* • R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477
- Carol A. Gloff* • Alkermes, Inc., Cambridge, Massachusetts 02139
- Marjorie A. Mohler* • Department of Safety Evaluation, Genentech, Inc., South San Francisco, California 94080
- Jerome A. Moore* • Department of Safety Evaluation, Genentech, Inc., South San Francisco, California 94080; *present address:* Celtrix Pharmaceuticals, Santa Clara, California 95052
- John B. Stoudemire* • Cytel Corporation, San Diego, California 92121
- John M. Trang* • Department of Pharmaceutical Sciences, Samford University Pharmacokinetics Center, School of Pharmacy, Samford University, Birmingham, Alabama 35229

Robert J. Wills • R. W. Johnson Pharmaceutical Research Institute,
Raritan, New Jersey 08869

Peter K. Working • Department of Pharmacology and Toxicology, Lipo-
some Technology, Inc., Menlo Park, California 94025

Victor J. Wroblewski • Lilly Research Laboratories, Lilly Corporate
Center, Indianapolis, Indiana 46285

Preface to the Series

A major challenge confronting pharmaceutical scientists in the future will be to design successful dosage forms for the next generation of drugs. Many of these drugs will be complex polymers of amino acids (e.g., peptides, proteins), nucleosides (e.g., antisense molecules), carbohydrates (e.g., polysaccharides), or complex lipids.

Through rational drug design, synthetic medicinal chemists are preparing very potent and very specific peptides and antisense drug candidates. These molecules are being developed with molecular characteristics that permit optimal interaction with the specific macromolecules (e.g., receptors, enzymes, RNA, DNA) that mediate their therapeutic effects. However, rational drug design does not necessarily mean rational drug delivery, which strives to incorporate into a molecule the molecular properties necessary for optimal transfer between the point of administration and the pharmacological target site in the body.

Like rational drug design, molecular biology is having a significant impact on the pharmaceutical industry. For the first time, it is possible to produce large quantities of highly pure proteins, polysaccharides, and lipids for possible pharmaceutical applications. The design of successful dosage forms for these complex biotechnology products represents a major challenge to pharmaceutical scientists.

Development of an acceptable drug dosage form is a complex process requiring strong interactions between scientists from many different divisions in a pharmaceutical company, including discovery, development, and manufacturing. The series editor, the editors of the individual volumes, and the publisher hope that this new series will be particularly helpful to scientists in the development areas of a pharmaceutical company (e.g., drug metabolism, toxicology, pharmacokinetics and pharmacodynamics, drug delivery, preformulation, formulation, and physical and analytical chemistry). In ad-

dition, we hope this series will help to build bridges between the development scientists and scientists in discovery (e.g., medicinal chemistry, pharmacology, immunology, cell biology, molecular biology) and in manufacturing (e.g., process chemistry, engineering). The design of successful dosage forms for the next generation of drugs will require not only a high level of expertise by individual scientists, but also a high degree of interaction between scientists in these different divisions of a pharmaceutical company.

Finally, everyone involved with this series hopes that these volumes will also be useful to the educators who are training the next generation of pharmaceutical scientists. In addition to having a high level of expertise in their respective disciplines, these young scientists will need to have the scientific skills necessary to communicate with their peers in other scientific disciplines.

RONALD T. BORCHARDT
Series Editor

Preface

Investigation of the pharmacokinetics and metabolism of human proteins has escalated over the last two decades because of the use of recombinant human proteins as therapeutic agents. In addition, the development and improvement of analytical techniques enabling the detection of minute quantities of proteins in biological matrices have aided this process.

In assembling this volume, we sought to provide a state-of-the-art assessment of the pharmacokinetics and metabolism of protein therapeutics through complete reviews of selected examples. A comprehensive review of all protein therapeutics was not attempted; the majority of the therapeutic protein classes and crucial scientific issues have been addressed, however. Therefore, we are confident that this volume will provide a useful reference for scientists in this field.

The volume has been divided into two general parts. The first part (Chapters 1–3) is composed of general reviews of topics of importance in pharmacokinetic/metabolism studies of proteins: goals and analytical methodologies, effects of binding proteins, and effects of antibody induction, respectively. The second part (Chapters 4–8) consists of specific, detailed reviews by therapeutic protein class: growth factors and hormones, cytokines, cardiovascular proteins, hematopoietic proteins, and antibodies, respectively.

The editors are grateful to the contributors for the patience, personal sacrifice and perseverance required to complete this volume.

BOBBE L. FERRAILOLO
MARJORIE A. MOHLER
CAROL A. GLOFF

Contents

Chapter 1

Goals and Analytical Methodologies for Protein Disposition Studies

Bobbe L. Ferraiolo and Marjorie A. Mohler

1. Introduction	1
2. Goals of Protein Disposition Studies	1
2.1. Fate of Intact Drug	2
2.2. Pharmacokinetic/Pharmacodynamic Correlations	2
2.3. Regimen-Dependent Effects	3
2.4. Binding Proteins	3
2.5. Catabolism of Protein Therapeutics	5
2.6. Drug-Drug Interactions	7
2.7. Interspecies Scaling	8
3. Methods	8
3.1. Immunoassays	9
3.2. Bioassays	14
3.3. Radiolabels	14
3.4. Other Analytical Methods	19
4. Future Directions	20
References	21

Chapter 2

Binding Proteins of Protein Therapeutics

Marjorie A. Mohler, Jennifer E. Cook, and Gerhard Baumann

1. Human Insulinlike Growth Factor-I	35
1.1. Structure	36
1.2. Actions	36
1.3. Regulation	37
1.4. Insulinlike Growth Factor Binding Proteins	38
2. Human Growth Hormone	44
2.1. High-Affinity Growth Hormone-Binding Protein	45
2.2. Low-Affinity Growth Hormone-Binding Protein	51
3. Human Tissue Plasminogen Activator	53
3.1. Structure and Function	54
3.2. Metabolism and Pharmacokinetics of rt-PA	54
3.3. Protease Inhibitors	55
References	59

Chapter 3

Potential Effects of Antibody Induction by Protein Drugs

Peter K. Working

1. Introduction	73
2. Antibodies to Recombinant Proteins	74
2.1. What Are Neutralizing Antibodies?	74
2.2. Detection of Antibodies	74
2.3. Real-Life Effects of Neutralizing Antibodies	75
3. Factors Contributing to Immunogenicity	76
3.1. Primary Structure	77
3.2. Tertiary Structure	77
3.3. Structural Complexity	78
4. Effects of Study Design	78
4.1. Route of Administration	79
4.2. Dosing Considerations	79
4.3. Genetic Considerations	80
4.4. The Effect of Disease on Antibody Induction	81
4.5. Miscellaneous Effects	81
5. Effects of Antibodies on Studies with Protein Drugs	82
5.1. Direct Nullification of Drug Action	83
5.2. Interference with Pharmacokinetics	84
5.3. Immune Complex Reactions	87
6. Overview	87
References	88

Chapter 4

Pharmacokinetics and Metabolism of Protein Hormones

Jerome A. Moore and Victor J. Wroblewski

1. Introduction	93
2. Human Insulin	94
2.1. Pharmacokinetics	94
2.2. Metabolism	95
3. Relaxin	98
3.1. Background	98
3.2. Metabolism	98
3.3. Pharmacokinetics	98
3.4. Tissue Distribution	101
3.5. Summary	101
4. Human Proinsulin	102
4.1. Background	102
4.2. Metabolism	102
5. Growth Hormone and Prolactin	103
5.1. Growth Hormone Background	103
5.2. Growth Hormone Pharmacokinetics	105
5.3. Species Scaling of Growth Hormone Pharmacokinetics	106
5.4. Metabolism of Growth Hormone and Prolactin	107
6. Parathyroid Hormone	110
6.1. Background	110
6.2. Pharmacokinetics	110
6.3. Metabolism	111
7. Atrial Natriuretic Factor	113
7.1. Background	113
7.2. Pharmacokinetics	114
7.3. Metabolism	114
8. Overview	115
References	117

Chapter 5

Pharmacokinetics and Metabolism of Therapeutic Cytokines

Carol A. Gloff and Robert J. Wills

1. Tumor Necrosis Factor	127
1.1. Chemistry	128

1.2. Analytical Techniques	128
1.3. Pharmacokinetics	128
2. Interferons	133
2.1. Chemistry	133
2.2. Analytical Considerations	135
2.3. Pharmacokinetics	135
References	142

Chapter 6

Pharmacokinetics and Metabolism of Cardiovascular Therapeutic Proteins

Paul A. Cossum and Robert A. Baughman, Jr.

1. Proteins of the Blood Coagulation Pathway	151
2. Factor VIII	153
2.1. Background	153
2.2. Endogenous Distribution	153
2.3. Pharmacokinetics	154
2.4. Metabolism	156
2.5. Antibodies	157
3. Factor IX	158
3.1. Background	158
3.2. Pharmacokinetics	158
3.3. Metabolism	160
3.4. Antibodies	160
4. Factor VII/VIIa	161
4.1. Background	161
4.2. Pharmacokinetics	161
5. Factor XIII	162
5.1. Background	162
5.2. Pharmacokinetics	163
6. Tissue Factor (Factor III)	163
6.1. Background	163
6.2. Pharmacokinetics	164
6.3. Metabolism/Inactivation	164
7. Fibrinolytic Therapeutic Proteins	165
8. Tissue Plasminogen Activator	166
8.1. Background	166
8.2. Analytical Issues	167

8.3. Pharmacokinetics	167
8.4. Metabolism	172
9. Streptokinase and Anisoylated Streptokinase	173
9.1. Background	173
9.2. Pharmacokinetics	174
10. Urokinase and Single-Chain Urokinase	175
10.1. Background	175
10.2. Pharmacokinetics	176
11. Conclusions	177
References	178

Chapter 7

Pharmacokinetics and Metabolism of Hematopoietic Proteins

John B. Stoudemire

1. Introduction	189
2. Erythropoietin	191
2.1. Epo Preclinical Pharmacokinetics	192
2.2. Epo Clinical Pharmacokinetics	197
3. Granulocyte-Colony Stimulating Factor	201
4. Granulocyte Macrophage-Colony Stimulating Factor	204
4.1. GM-CSF Preclinical Pharmacokinetics	204
4.2. GM-CSF Clinical Pharmacokinetics	206
5. Macrophage-Colony Stimulating Factor	208
6. Conclusions	212
References	213

Chapter 8

Pharmacokinetics and Metabolism of Therapeutic and Diagnostic Antibodies

John M. Trang

1. Introduction	223
1.1. Background	223
1.2. Overview of Immunoglobulins	225
2. Pharmacokinetics and Metabolism of Murine Antibodies	227
2.1. Murine Native and Radioimmunoconjugate Antibodies and Fragments	227

2.2. Murine Chemoimmunoconjugate Antibodies and
Fragments 236

2.3. Murine Immunotoxin Antibodies and Fragments 240

3. Pharmacokinetics and Metabolism of Nonmurine, Human,
and Chimeric Antibodies 247

3.1. Nonmurine Polyclonal Antibodies 247

3.2. Human Antibodies and Fragments 251

3.3. Chimeric Antibodies and Fragments 255

4. Conclusions 260

4.1. Summary of Antibody Pharmacokinetics 260

4.2. Factors Influencing Antibody Pharmacokinetics 261

4.3. Limitations of Monoclonal Antibody Applications in
Diagnosis and Therapy 262

4.4. Recommendations for Future Study 263

References 264

Index 271

Chapter 1

Goals and Analytical Methodologies for Protein Disposition Studies

Bobbe L. Ferraiolo and Marjorie A. Mohler

1. INTRODUCTION

This chapter will present an overview of the goals of protein disposition studies and some of the analytical tools used to achieve those goals. The examples cited in the goals portion of this chapter will be briefly presented since these will be explored in greater depth in the ensuing chapters. Analytical issues are of major concern in protein disposition studies since many of the standard protein analysis methods do not individually provide a positive identification of the analyte. The question of which existing methodologies and analytical technologies are most productive will be addressed.

2. GOALS OF PROTEIN DISPOSITION STUDIES

The questions that need to be addressed in protein disposition studies are the same as those that are addressed for conventional drugs (Table I).

Bobbe L. Ferraiolo • R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477. *Marjorie A. Mohler* • Department of Safety Evaluation, Genentech, Inc., South San Francisco, California 94080.

Protein Pharmacokinetics and Metabolism, edited by Bobbe L. Ferraiolo *et al.* Plenum Press, New York, 1992.